Skip header and navigation

3 records – page 1 of 1.

[Characteristics of the immune system parameters in residents of the Far Eastern region during physiological aging].

https://arctichealth.org/en/permalink/ahliterature123354
Source
Adv Gerontol. 2012;25(1):68-71
Publication Type
Article
Date
2012
Author
T A Gvozdenko
O Iu Kytikova
T I Vitkina
P V Borshchev
Source
Adv Gerontol. 2012;25(1):68-71
Date
2012
Language
Russian
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Aging - blood - immunology - physiology
Data Interpretation, Statistical
Female
GPI-Linked Proteins - immunology
HLA-DR Antigens - immunology
Humans
Immune System - physiology
Immunoglobulins - blood
Interleukin-2 Receptor alpha Subunit - immunology
Lymphocyte Count
Male
Middle Aged
Receptors, IgG - immunology
Russia
T-Lymphocytes - cytology - immunology
Young Adult
Abstract
We studied the basic indicators of immune status of healthy persons of different age groups living in the monsoon climate in the southern Far East. The analysis shows age-dependent development of immunodepressive status, combined with increasing levels of CD16, CD25 and HLA-DR in the aging organism. Climatic and anthropogenic factors effect profoundly damaging on the body, which results in the severity of disorders of the immune system in old, old age and longevity.
PubMed ID
22708447 View in PubMed
Less detail

GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients.

https://arctichealth.org/en/permalink/ahliterature283191
Source
Clin Immunol. 2017 Mar;176:114-121
Publication Type
Article
Date
Mar-2017
Author
Mikael Pihl
Hugo Barcenilla
Stina Axelsson
Mikael Chéramy
Linda Åkerman
Ingela Johansson
Johnny Ludvigsson
Rosaura Casas
Source
Clin Immunol. 2017 Mar;176:114-121
Date
Mar-2017
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Child
Diabetes Mellitus, Type 1 - drug therapy - immunology
Double-Blind Method
Female
Follow-Up Studies
Glutamate Decarboxylase - administration & dosage
Humans
Interleukin-2 Receptor alpha Subunit - immunology
Interleukin-7 Receptor alpha Subunit - immunology
Lymphocyte Activation - drug effects - immunology
Male
Sweden
T-Lymphocytes, Regulatory - drug effects - immunology
Young Adult
Abstract
Administration of Glutamic Acid Decarboxylase (GAD)65 formulated in aluminium hydroxide preserved insulin secretion in a phase II trial in recent onset Type 1 Diabetes. A subsequent European phase III trial was closed at 15months after failing to reach primary endpoint, but the majority of the Swedish patients completed the 21months follow-up. We studied the frequencies and phenotype of T cells, suppressive capacity of Tregs, GAD65-induced proliferation, and frequencies of T cells with a GAD65-specific TCR in Swedes participating in the trial. Stimulation with GAD65 induced activated T cells and also cells with a suppressive phenotype. Activated GAD65-specific effector T cells were detected by tetramer staining while the frequency of GAD65-specific Treg was not affected by the treatment. Additional doses of GAD-alum increased frequencies of CD25(+)CD127(+), but had no effect on CD25(hi)CD127(lo). Our findings indicate that GAD-alum treatment primarily induced activated T cells. GAD65-specific cells were mainly of activated phenotype.
PubMed ID
28131926 View in PubMed
Less detail

Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells.

https://arctichealth.org/en/permalink/ahliterature90656
Source
Crit Rev Oncog. 2008;14(1):57-77
Publication Type
Article
Date
2008
Author
Yaqub Sheraz
Taskén Kjetil
Author Affiliation
The Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, N-0317 Oslo, Norway.
Source
Crit Rev Oncog. 2008;14(1):57-77
Date
2008
Language
English
Publication Type
Article
Keywords
Animals
Antigens, CD - immunology
Antigens, CD4 - immunology
Colorectal Neoplasms - drug therapy
Cyclic AMP - physiology
Cyclic AMP-Dependent Protein Kinases - physiology
Cyclooxygenase Inhibitors - therapeutic use
Disease Models, Animal
Humans
Interleukin-2 Receptor alpha Subunit - immunology
Lymphocyte Depletion
Neoplasms - immunology
Signal Transduction
T-Lymphocytes, Regulatory - immunology
Abstract
CD4+CD25+ regulatory T (Treg) cells are engaged in the maintenance of immunological self-tolerance and suppressive control of excessive immune responses to foreign antigens. Furthermore, Treg cells infiltrate tumor tissues and may impede immune surveillance against cancer and hamper the development of an effective antitumor immunity. Depletion of Treg cells in animal models has been demonstrated to provoke tumor immunity. Attenuation of Treg-mediated suppression is therefore an interesting strategy to enhance antitumor responses. We recently found that adaptive Treg cells express COX-2 and suppress responder T cells in a PGE2-cAMP-dependent manner, which can be reversed by COX-2 inhibitors or EP-receptor antagonists. The same mechanism also appeared to be operative in patients with colorectal cancer where treatment with COX-inhibitor or cAMP-antagonist enhanced antitumor immune responses to the same extent as depletion of Treg cells. This provides mechanism-based opportunities for pharmacological intervention to interfere with Treg immunosuppression. In this review we will discuss key mechanisms used by Treg cells to suppress antitumor immunity, with emphasis on the cAMP-PKA pathway. We will also highlight some of the roles of Treg cells in cancer.
PubMed ID
19105570 View in PubMed
Less detail